Alpha 2.0
Login Register
» Authors » Jan Paul de Boer

Jan Paul de Boer

Explore the profile of Jan Paul de Boer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 2185
Followers 0
Related Specialties
Oncology
General Surgery
Radiology
Top 10 Co-Authors
Flora E van Leeuwen
Charlotte L Zuur
Daphne de Jong
Alfons J M Balm
Abrahim Al-Mamgani
Berthe M P Aleman
Michael Hauptmann
Coen R N Rasch
Pieternella J Lugtenburg
Arash Navran
Published In
Head Neck
Blood
Radiother Oncol
J Clin Oncol
Nat Commun
Affiliations
Soon will be listed here.
Recent Articles
11.
Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer
de Roest R, van der Heijden M, Wesseling F, de Ruiter E, Heymans M, Terhaard C, et al.
Radiother Oncol . 2022 Aug; 175:112-121. PMID: 35973619
Background: Definitive concomitant cisplatin-based chemoradiotherapy (CRT) is the current gold standard for most patients with advanced stage head and neck squamous cell carcinoma (HNSCC) of the pharynx and larynx. Since...
12.
Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center
Piek M, de Vries L, Donswijk M, de Keizer B, de Boer J, Lodewijk L, et al.
Eur J Nucl Med Mol Imaging . 2022 Jan; 49(7):2392-2400. PMID: 35031811
Purpose: A prostate-specific membrane antigen (PSMA) thyroid incidentaloma (PTI) is an unexpected, PSMA-avid thyroid lesion, newly detected during the investigation of an unrelated condition using PSMA PET/CT. The aim of...
13.
[F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma
Vos J, Zuur C, Smit L, de Boer J, Al-Mamgani A, van den Brekel M, et al.
Eur J Nucl Med Mol Imaging . 2021 Dec; 49(6):2010-2022. PMID: 34957526
Purpose: To investigate the utility of [F]FDG-PET as an imaging biomarker for pathological response early upon neoadjuvant immune checkpoint blockade (ICB) in patients with head and neck squamous cell carcinoma...
14.
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
Vos J, Elbers J, Krijgsman O, Traets J, Qiao X, van der Leun A, et al.
Nat Commun . 2021 Dec; 12(1):7348. PMID: 34937871
Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non-randomized phase Ib/IIa trial, 32 HNSCC patients are treated...
15.
Development and external validation of a prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer
Willemsen A, Kok A, Baijens L, de Boer J, de Bree R, Devriese L, et al.
Clin Nutr . 2021 Dec; 41(1):177-185. PMID: 34883306
Background & Aims: Patients who receive chemoradiotherapy or bioradiotherapy (CRT/BRT) for locally advanced head and neck squamous cell carcinoma (LAHNSCC) often experience high toxicity rates interfering with oral intake, causing...
16.
The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin
Bril S, Al-Mamgani A, Chargi N, Remeijer P, Devriese L, de Boer J, et al.
Head Neck . 2021 Oct; 44(1):189-200. PMID: 34713519
Background: Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose-limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy...
17.
Retrospective Analyses of FDG-PET/CT Thyroid Incidentaloma in Adults: Incidence, Treatment, and Outcome in a Tertiary Cancer Referral Center
Piek M, de Boer J, Vriens M, van Leeuwaarde R, Stokkel M, Hartemink K, et al.
Thyroid . 2021 Aug; 31(11):1715-1722. PMID: 34340567
A thyroid incidentaloma (TI) is an unexpected, asymptomatic thyroid lesion discovered during the investigation of an unrelated condition. The aim of the present study is to examine the incidence of...
18.
Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes
Al-Mamgani A, Kessels R, Navran A, Hamming-Vrieze O, Zuur C, de Boer J, et al.
Radiother Oncol . 2021 Jul; 162:170-177. PMID: 34311003
Background And Purpose: We aim to retrospectively investigate whether reducing GTV to high-risk CTV margin will significantly reduce acute and late toxicity without jeopardizing outcome in head-and-neck squamous cell carcinoma...
19.
Defining High-Quality Integrated Head and Neck Cancer Care Through a Composite Outcome Measure: Textbook Outcome
van der Heide M, de Jel D, Hoeijmakers F, Hoebers F, de Boer J, Hamming-Vrieze O, et al.
Laryngoscope . 2021 Jul; 132(1):78-87. PMID: 34216399
Objectives/hypothesis: To further improve the quality of head and neck cancer (HNC) care, we developed a composite measure defined as "textbook outcome" (TO). Methods: We analyzed a retrospective cohort of...
20.
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer
Bourhis J, Stein A, de Boer J, Van den Eynde M, Gold K, Stintzing S, et al.
Cancer Treat Rev . 2021 May; 97:102172. PMID: 33989949
Treatment outcomes have improved with the advent of immune checkpoint inhibitors and small molecule inhibitors. However, many patients do not respond with single agents. Consequently, ongoing research is focused on...